You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

SOS1 Inhibitor

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Nasopharyngeal Carcinoma Trial in Guangzhou (Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel),

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)
  • +3 more
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Sep 17, 2022

Oxidative Stress, Cardiovascular Diseases, Bacopaside II Trial in Brussels (KeenMind, Placebo)

Recruiting
  • Oxidative Stress
  • +6 more
  • KeenMind
  • Placebo
  • Brussels, Belgique, Belgium
    Cliniques Universitaires Saint Luc
Sep 22, 2023

Severe Aplastic Anemia, Single Lineage Cytopenias, T-LGL, Hypoplastic MDS Trial run by the National Heart, Lung, and Blood

Not yet recruiting
  • Severe Aplastic Anemia
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 23, 2023

Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy Trial in Wuhan (drug, procedure, radiation)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Neoadjuvant Therapy
  • 3cycles (Toripalimab + cetuximab)
  • +2 more
  • Wuhan, Hebei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Aug 6, 2023

Malignant Ascites Trial (Serplulimab, Molgramostim, Hypofractionated radiotherapy/Sterotactic body radiotherapy)

Not yet recruiting
  • Malignant Ascites
  • (no location specified)
Aug 11, 2022

Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II Trial (PHA-022121 low dose, PHA-022121 medium

Recruiting
  • Hereditary Angioedema
  • +11 more
  • PHA-022121 low dose
  • +3 more
  • Birmingham, Alabama
  • +7 more
Dec 5, 2022

Advanced Solid Tumor Trial in Xuzhou (Oncolytic Virus Injection(Revottack)+PD-1)

Not yet recruiting
  • Advanced Solid Tumor
  • Oncolytic Virus Injection（Revottack）+PD-1
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Dec 1, 2022

Primary Aldosteronism, Endocrine Hypertension Trial (Cinnarizine, NIFEdipine ER)

Not yet recruiting
  • Primary Aldosteronism
  • Endocrine Hypertension
  • (no location specified)
Jan 12, 2023

Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy Trial (radiation, drug, biological)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • +3 more
  • Intensity Modulated Radiation Therapy
  • +3 more
  • (no location specified)
Jul 11, 2023

HIPEC Combined With PD1/PDL1 Inhibitor for Gastric Cancer With

Not yet recruiting
  • Gastric Cancer
  • Observational
  • (no location specified)
Dec 13, 2022

Advanced Lung Squamous Cell Carcinoma Trial in Chengdu (low-dose radiation therapy and stereotactic body radiation therapy,

Not yet recruiting
  • Advanced Lung Squamous Cell Carcinoma
  • low-dose radiation therapy and stereotactic body radiation therapy
  • +2 more
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
Nov 13, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • BTK inhibitor
  • PD-1 inhibitor
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
May 20, 2023

Locally Advanced Rectal Cancer Trial in Beijing (capecitabine, tislelizumab, thymalfasin)

Not yet recruiting
  • Locally Advanced Rectal Cancer
  • Beijing, China
  • +1 more
Sep 21, 2023

Acute Myeloid Leukemia, Lymphoma, Mantle-Cell Trial (PEP07)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Lymphoma, Mantle-Cell
  • (no location specified)
Dec 22, 2022

Classical Hodgkin Lymphoma, Refractory or Relapsed Classical Hodgkin Lymphoma Trial in Guangzhou (PD-1 inhibitor, PD-1

Recruiting
  • Classical Hodgkin Lymphoma
  • Refractory or Relapsed Classical Hodgkin Lymphoma
  • PD-1 inhibitor
  • PD-1 inhibitor, gemcitabine, vinorelbine and doxorubicin liposome
  • Guangzhou, Guangdong, China
  • +2 more
May 6, 2022

Solid Tumor, Adult Trial in Orlando, Cincinnati (ADA-011, PD(L)-1 inhibitor)

Recruiting
  • Solid Tumor, Adult
  • Orlando, Florida
  • +1 more
Jan 6, 2023

COPD (COPD), Alpha1-Antitrypsin Deficiency Trial (ARALAST NP, Another Available A1PI)

Not yet recruiting
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Alpha1-Antitrypsin Deficiency
  • ARALAST NP
  • Another Available A1PI
  • (no location specified)
Jul 18, 2022

Advanced Solid Tumor, NSCLCs Trial in Houston (Adagrasib, Olaparib)

Not yet recruiting
  • Advanced Solid Tumor
  • Non-small Cell Lung Cancers
  • Houston, Texas
    M D Anderson Cancer Center
Nov 15, 2023

Breast Cancer, Ovarian Cancer, Pancreas Cancer Trial (TNG348, Olaparib)

Not yet recruiting
  • Breast Cancer
  • +7 more
  • (no location specified)
Sep 26, 2023

Neurofibromatosis 1 Trial run by the National Cancer Institute (NCI) (Abemaciclib)

Recruiting
  • Neurofibromatosis 1
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Hepatocellular Carcinoma Trial in Beijing (iNKT Cells, PD-1, Regorafenib)

Not yet recruiting
  • Hepatocellular Carcinoma
  • iNKT Cells
  • +2 more
  • Beijing, Beijing, China
    Beijing Youan Hospital,Capital Medical University
Jul 24, 2023

Steroid-refractory Diamond-Blackfan Anemia (DBA) Trial run by the National Heart, Lung, and Blood Institute (NHLBI) (Bitopertin)

Not yet recruiting
  • Steroid-refractory Diamond-Blackfan Anemia (DBA)
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Apr 28, 2023

Development ofEORTC Immune Checkpoint Inhibitor-specific Quality

Recruiting
  • Cancer
  • +2 more
    • Paris, France
      Institut Curie
    Nov 2, 2022

    Healthy Adults Trial in Daytona Beach (Adagrasib, Eltrombopag + adagrasib)

    Recruiting
    • Healthy Adults
    • Daytona Beach, Florida
      Fortrea Clinical Research Unit Daytona Beach (Labcorp Clinical R
    Jun 29, 2023

    Advanced Solid Tumor Trial (HLX23)

    Withdrawn
    • Advanced Solid Tumor
    • Los Angeles, California
    • +5 more
    Jan 13, 2023